PHI with Fibroplastic parietal endocarditis
How does this condition affect your private health insurance?
Endocarditis parietalis fibroplastica, commonly known as Loeffler's endocarditis, is a rare and severe form of restrictive cardiomyopathy. It is characterized by progressive fibrous thickening and infiltration of the heart's inner lining (endocardium), often associated with persistent hypereosinophilia. This pathological process impairs the heart's ability to fill properly during diastole, leading to severe diastolic dysfunction and heart failure. Thrombi frequently form on the damaged endocardium, posing a high risk of systemic embolization. The disease can affect one or both ventricles, causing symptoms like dyspnea, fatigue, and edema. Without prompt diagnosis and management, particularly of the underlying eosinophilia, it is often progressive and life-threatening.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several weeks to months for initial symptomatic presentation.
Duration of Illness (Lifetime)
Chronic and progressive without effective treatment, often leading to heart failure over several years.
Cost of Treatment (Initial)
High (e.g., $50,000 - $150,000 for initial diagnosis, hospitalization, and immunosuppressive therapy).
Cost of Treatment (Lifetime)
Very high (e.g., $200,000 - $1,000,000+ including chronic medication, regular monitoring, potential surgical interventions like valve replacement or heart transplantation).
Mortality Rate
High (e.g., 50% mortality within 5 years for severe, untreated cases, significantly reduced with effective management of underlying hypereosinophilia).
Risk of Secondary Damages
Very high (e.g., >80% probability of heart failure, arrhythmias, thromboembolic events, pulmonary hypertension, and other organ damage from eosinophilia).
Probability of Full Recovery
Low (e.g., <20% complete recovery without any residual cardiac dysfunction; treatment can halt progression and improve symptoms but structural damage is often irreversible).
Underlying Disease Risk
Very high (e.g., >70% probability of underlying hypereosinophilic syndrome, either primary/clonal or secondary to other conditions like myeloproliferative neoplasms or parasitic infections).